Wednesday, 20 November 2024

Yield10 Bioscience Announces Closing of $3.7 Million Public Offering

Yield10 Bioscience Successfully Completes $3.7 Million Public Offering to Support Innovative Agricultural Advancements

Yield10 Bioscience, Inc., an agricultural bioscience company,  announced the closing of its previously announced public offering of 5,750,000 units at a public offering price of $0.65 per unit. Each unit consisted of one share of common stock and one warrant to purchase one share of common stock. The warrants are immediately exercisable at an exercise price of $0.65 per share and expire five years from the date of issuance. The shares of common stock and accompanying warrants could only be purchased together in this offering but were issued separately and are immediately separable upon issuance.

Gross proceeds, before deducting placement agent fees and other offering expenses, were approximately $3.7 million.

Maxim Group LLC and Lake Street Capital Markets, LLC acted as joint placement agents for the offering.

The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-273240) that was filed with the U.S. Securities and Exchange Commission (“SEC”) on July 14, 2023, as amended on August 2, 2023, and declared effective on August 10, 2023. The offering was made only by means of a prospectus which is part of the registration statement. A final prospectus relating to and describing the terms of the public offering was filed with the SEC.   Copies of the final prospectus relating to the offering may be obtained at the SEC’s website www.sec.gov. Alternatively, copies of the final prospectus may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, New York 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745, or from Lake Street Capital Markets, LLC, Attention: Syndicate Department, 920 Second Avenue South, Suite 700, Minneapolis, Minnesota 55402, or by emailing syndicate@lakestreetcm.com or by calling (612) 326-1305.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Published on : 16th August, 2023